Literature DB >> 33543384

Treatment of advanced stage osteochondrosis dissecans in the adolescent elbow using a hyaloronic acid-based scaffold: a case series of 5 patients.

Sebastian Farr1, Matthias Pallamar2, Theresa Eder3, Rudolf Ganger2.   

Abstract

INTRODUCTION: Osteochondrosis dissecans (OCD) is considered to be one of the main causes for pain, discomfort and morbidity in the pediatric elbow joint. Few treatment options, such as microfracture or autologous transplantation, of osteochondral bone grafts have been described to address advanced OCD. The aim of this retrospective case series is to present preliminary clinical and radiologic findings following advanced stage OCD repair using a novel combination of a hyaluronic acid-based scaffold with autologous iliac crest bone grafting.
MATERIALS AND METHODS: Five adolescents, who underwent treatment of OCD (grade 3 or 4 according to Nelson) using a combination technique of defect debridement, transplantation of cancellous iliac crest bone and application of a HYALOFAST® membrane (Anika Therapeutics S.r.L., Italy), were re-assessed using clinical and radiologic examinations (defect diameter, depth, sclerosis, congruency, fragmentation, dissection, radiolucency, growth plate status; MRI) after a minimum of 2 years (mean, 34 months; range, 24-45) postoperatively. Dedicated outcome scores (Numeric Rating Scale [NRS], Pediatric Outcome Data Collection Instrument [PODCI], Mayo Elbow Performance Score [MEPS], and Timmerman-Andrews Score [TIMM] were collected.
RESULTS: All patients reported a NRS score of 0. The mean total TIMM, MEPS and PODCI (Global Functioning Scale) scores were 189 (range 165-200), 94 (range, 70-100), and 92 (range 83-98; normative score 47; range 35-55), respectively, indicating good to excellent clinical outcomes. The radiographic analysis showed overall improvements with regard to OCD width and depth reduction (35%, - 27-100%; 52%, 4-100%), but full resolution in only 2 of 5 cases. Elbow motion improved slightly after surgery. No complications were noted.
CONCLUSION: This study showed promising clinical short- to mid-term results in adolescent patients with advanced OCD using a novel surgical treatment combination. Radiographic results showed partial healing; hence, residual changes should be monitored over a longer period.

Entities:  

Keywords:  AMIC; Bone graft; Osteochondritis; Osteochondrosis dissecans; Pediatric elbow

Year:  2021        PMID: 33543384     DOI: 10.1007/s00402-021-03773-8

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  34 in total

1.  Prevalence of Capitellar Osteochondritis Dissecans in Children With Chronic Radial Head Subluxation and Dislocation.

Authors:  Delma Y Jarrett; Michele M Walters; Paul K Kleinman
Journal:  AJR Am J Roentgenol       Date:  2016-03-24       Impact factor: 3.959

2.  Bilateral Osteochondritis Dissecans of the Capitellum in Fraternal Twins: A Case Report.

Authors:  Tetsuya Matsuura; Keizo Wada; Naoto Suzue; Toshiyuki Iwame; Shoji Fukuta; Koichi Sairyo
Journal:  JBJS Case Connect       Date:  2017 Jul-Sep

3.  Osteochondritis dissecans of the elbow: histopathological assessment of the articular cartilage and subchondral bone with emphasis on their damage and repair.

Authors:  Tomomi Kusumi; Yasuyuki Ishibashi; Eiichi Tsuda; Akinori Kusumi; Masanori Tanaka; Fuyuki Sato; Satoshi Toh; Hiroshi Kijima
Journal:  Pathol Int       Date:  2006-10       Impact factor: 2.534

4.  Cumulative Incidence of Osteochondritis Dissecans of the Capitellum in Preadolescent Baseball Players.

Authors:  Tetsuya Matsuura; Toshiyuki Iwame; Naoto Suzue; Shoichiro Takao; Susumu Nishio; Kokichi Arisawa; Koichi Sairyo
Journal:  Arthroscopy       Date:  2019-01       Impact factor: 4.772

5.  Nonoperative treatment for osteochondritis dissecans of the capitellum.

Authors:  Kenichi Mihara; Hiroaki Tsutsui; Naoya Nishinaka; Ken Yamaguchi
Journal:  Am J Sports Med       Date:  2008-12-04       Impact factor: 6.202

6.  Childhood Obesity is Associated With Osteochondritis Dissecans of the Knee, Ankle, and Elbow in Children and Adolescents.

Authors:  Jeffrey I Kessler; John C Jacobs; Peter C Cannamela; Kevin G Shea; Jennifer M Weiss
Journal:  J Pediatr Orthop       Date:  2018 May/Jun       Impact factor: 2.324

7.  Demographics and Epidemiology of Osteochondritis Dissecans of the Elbow Among Children and Adolescents.

Authors:  Jeffrey I Kessler; John C Jacobs; Peter C Cannamela; Jennifer M Weiss; Kevin G Shea
Journal:  Orthop J Sports Med       Date:  2018-12-19

8.  The Incidence of Surgery in Osteochondritis Dissecans in Children and Adolescents.

Authors:  Jennifer M Weiss; Hooman Nikizad; Kevin G Shea; Samvel Gyurdzhyan; John C Jacobs; Peter C Cannamela; Jeffrey I Kessler
Journal:  Orthop J Sports Med       Date:  2016-03-16

9.  Arthroscopic Fragment Resection for Capitellar Osteochondritis Dissecans in Adolescent Athletes: 5- to 12-Year Follow-up.

Authors:  Yusuke Ueda; Hiroyuki Sugaya; Norimasa Takahashi; Keisuke Matsuki; Morihito Tokai; Kazutomo Onishi; Shota Hoshika; Hiroshige Hamada
Journal:  Orthop J Sports Med       Date:  2017-12-15

Review 10.  Predictive Role of Symptom Duration Before the Initial Clinical Presentation of Adolescents With Capitellar Osteochondritis Dissecans on Preoperative and Postoperative Measures: A Systematic Review.

Authors:  Christopher Cheng; Matthew D Milewski; Jeffrey J Nepple; Hannah S Reuman; Carl W Nissen
Journal:  Orthop J Sports Med       Date:  2019-02-13
View more
  2 in total

1.  Autologous Minced Cartilage Implantation for Arthroscopic One-Stage Treatment of Osteochondritis Dissecans of the Elbow.

Authors:  Christian Ophoven; Ferdinand C Wagner; Kaywan Izadpanah; Martin Jaeger; Gian M Salzmann; Bruno Gladbach; Hagen Schmal; Dirk Maier
Journal:  Arthrosc Tech       Date:  2022-02-28

2.  Hypothermic Storage of 3D Cultured Multipotent Mesenchymal Stromal Cells for Regenerative Medicine Applications.

Authors:  Irena Vackova; Eliska Vavrinova; Jana Musilkova; Vojtech Havlas; Yuriy Petrenko
Journal:  Polymers (Basel)       Date:  2022-06-23       Impact factor: 4.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.